TCM
PETX

Tygh Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Tygh Capital Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-108,217
Closed -$1.73M – 121
2015
Q1 		$1.73M Buy
108,217
+43,807
+68% +$779K 0.32% 87
2014
Q4 		$1.15M Buy
+64,410
New +$803K 0.22% 101

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tygh Capital Management's PETX Position: Q2 2015 in Review

Tygh Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2015, closing a stake of 108,217 shares — an estimated $1.73M sold.

Tygh Capital Management first reported a position in PETX in Q4 2014 and held it in 2 quarters. The position peaked at $1.73M in Q1 2015. 92 funds tracked by Wall St. Rank hold PETX as of Q2 2015.

  • Tygh Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Tygh Capital Management sold 108,217 Aratana Therapeutics, Inc. shares in Q2 2015, an estimated $1.73M.
  • Tygh Capital Management first reported a position in Aratana Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
  • Tygh Capital Management's Aratana Therapeutics, Inc. position peaked at $1.73M in Q1 2015.
  • 92 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2015.

Based on Tygh Capital Management's 13F filing for Q2 2015, filed 10 Aug 2015.